Key change in the dome of Novo Nordisk, one of the large world pharmaceutical groups, which has become one of the main companies in the segment of treatments against obesity and diabetes, such as the popular Ozempic and Wegovy. The company has communicated this Friday that its CEO, Lars Fruergaard Jorgensen, has presented the resignation. An exit that comes after the strong punishment suffered by the actions, especially since mid -2024.
“Considering the recent market challenges, the fall in the price of shares and the desire of the Novo Nordisk Foundation, the Board of Directors of Novo Nordisk and Lars Fruergaard Jorgensen have completed together that implementing the succession of the CEO is the best for the company and its shareholders,” said the Danish pharmaceutical company in a statement.
Jorgesen will continue as CEO to the election of the substitute, to facilitate the transition period. The manager joined Novo Nordisk in 1991 and amounted to the position of CEO in January 2017. The firm has indicated that in the last eight years it has tripled its sales and its benefits, thanks to its strong portfolio of products and the leadership of the management team.
The company, however, has indicated that the substitute will be announced soon. In relation to the changes, Lars Rebien Sørensen, president of the Novo Nordisk Foundation, will join the Board of Directors, initially as an observer. However, the company’s intention is for the manager to join the Board of Shareholders of 2026.
After being one of the great European stars, becoming the first company of the old continent for stock market capitalization, in hard competition with LVMH and SAP, Novo Nordisk has suffered a hard punishment in recent times. The company, which competes with firms such as Eli Lilly, has seen how its actions fell more than a third since the beginning of January and more than 50% of its value during the last year.
After the announcement of the future change in the directive dome, the actions of the pharmacist has deepened the falls, getting to lower more than 3% last noon. Finally, the titles have closed the day with a decrease of 1.81%.
Helge Lund, president of the Board of Directors of Novo Nordisk, has affirmed that the pharmaceutical strategy remains unchanged, and added that “the Council trusts the company’s current business plans and in its ability to execute them.”
During the first quarter of the year, Novo Nordisk recorded a benefit of 29,030 million Danish crowns (about 3,890 million euros), a figure that represents a 14% growth in relation to the same period of the previous year. Sales amounted to 10,464 million euros, 19% more, thanks to the treatments against obesity, which raised their sales 67%.
For more updates, visit our homepage: NewsTimesWire
